Elite Pharmaceuticals Inc (ELTP)

[imanjen13]

The blowout 64% increase from quarter 1 to quarter 2 which reported 14.1 M in revenue, albeit somewhat skewed by an extraordinary gain, has cause more than half the guesses here to predict a 20m+ 3rd quarter. As previously noted, this years revenues will be boosted by the Prasco Adderall manufacturing deal with a initial delivery in December although the contact actually started in January.

With the Adderall shortage, it has been reported that the DEA, which controls the quota allotment, has probably given Elite at least a modest increase, and Elite has helped Prasco apply for their quota since they previously had no quota as a seller of the authorized generic.

My concern is that a 3rd quarter report at or near 14m will be considered disappointing by new investors who do not follow the company as closely as many here. Should that happen, it will be a great buying opportunity before the conference call when Nasrat make important forward looking statements regarding future revenue, the Purdue litigation and the progress of the needle movers.